

Subscription and Business Information

The American Journal of Psychiatry, ISSN 0002-953X, is published monthly by the American Psychiatric Association.

The American Psychiatric Association does not hold itself responsible for statements made in its publications by contributors or advertisers. Unless so stated, material in *The American Journal of Psychiatry* does not reflect the endorsement, official attitude, or position of the American Psychiatric Association or of the Journal's Editorial Board.

Periodicals postage paid at Washington, DC, and additional mailing offices. POSTMASTER: Send address changes to *The American Journal of Psychiatry*, Circulation Department, American Psychiatric Association, 800 Maine Avenue, S.W., Suite 900, Washington, D.C. 20024.

Editorial Office

American Journal of Psychiatry
American Psychiatric Association
800 Maine Avenue, S.W., Suite 900
Washington, D.C. 20024
E-mail: ajp@psych.org

Customer Service

Phone: (800) 368-5777 (toll-free)
E-mail: appi@psych.org

APA Member Subscription Services

Phone: (888) 35-PSYCH (toll-free)

Subscriptions

Regular and resident-fellow members in the U.S. receive print and online access as a **member benefit**. Subscriptions for non-members start at \$378 per year. Online only subscriptions start at \$342 per year. Go to <https://www.appi.org/ajp> for more information.

Institutional subscriptions are tier priced. For institutional site license or pricing information, contact (202) 559-3729 or institutions@psych.org.

Additional subscription options, including single issues and student rates
Contact Customer Service

Advertising

Pharmaceutical Print and Online Advertising
Frank Cox, Kathleen Harrison, Tim Wolfinger
Pharmaceutical Media, Inc.
30 East 33rd Street
New York, NY 10016
Phone: (212) 904-0379
E-mail: twolfinger@pminy.com

Nonpharmaceutical and Online Sales
Eamon Wood
Pharmaceutical Media, Inc.
E-mail: ewood@pminy.com
(see address and phone above).

Permissions and Reprints

Material published in the journals of the American Psychiatric Association and American Psychiatric Association Publishing is protected by copyright and all rights are reserved. Material may not be reproduced in any form or by any means without written permission from the copyright owner. For permission to reproduce material published by APA, please visit <http://www.appi.org/customer-service/permissions> for more information. Permission can also be secured through the Copyright Clearance Center (www.copyright.com).

APA does not require that permission be obtained for the photocopying of isolated articles for nonprofit classroom or library reserve use; all fees associated with such permission are waived. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Requests for commercial distribution and bulk reprints should be directed to (202) 609-7075.

Indexed in Abstracts for Social Workers, Academic Abstracts, Biological Abstracts, Chemical Abstracts, Chicago Psychoanalytic Literature Index, Cumulative Index to Nursing Literature, Excerpta Medica, Hospital Literature Index, Index Medicus, International Nursing Index, Nutrition Abstracts, Psychological Abstracts, Science Citation Index, Social Science Source, and Social Sciences Index.

Pages are produced by KnowledgeWorks Global (Waterbury, VT) and printed by Sheridan NH (Hanover, NH) on acid-free paper effective with Volume 169, Number 1, January 2012.

© 2022 American Psychiatric Association.



Officers 2021–2022

President

Vivian B. Pender, M.D.

President-Elect

Rebecca W. Brendel, M.D., J.D.

Treasurer

Richard F. Summers, M.D.

Secretary

Sandra M. DeJong, M.D., M.Sc.

Assembly

Speaker

Mary Jo Fitz-Gerald, M.D., M.B.A.

Speaker-Elect

Adam Nelson, M.D.

Recorder

Vasilis K. Pozios, M.D.

Office of the CEO and Medical Director

CEO and Medical Director

Saul Levin, M.D., M.P.A., F.R.C.P.-E.

Board of Trustees

Elie G. Aoun, M.D., M.R.O.

Jenny L. Boyer, M.D., Ph.D., J.D.

Kenneth Certa, M.D.

Jeffrey L. Geller, M.D., M.P.H.

Glenn A. Martin, M.D.

Eric M. Plakun, M.D.

Michele Reid, M.D.

Mary Hasbah Roessel, M.D.

Bruce J. Schwartz, M.D.

Altha J. Stewart, M.D.

Felix Torres, M.D., M.B.A.

Sanya Virani, M.D., M.P.H.

Cheryl D. Wills, M.D.

Urooj Yazdani, M.D.

Melinda Young, M.D.

Editorial Board

Editor-in-Chief

Ned H. Kalin, M.D.

Deputy Editors

Elisabeth Binder, M.D., Ph.D.

Kathleen T. Brady, M.D., Ph.D.

David A. Lewis, M.D.

Daniel S. Pine, M.D.

Carolyn Rodriguez, M.D., Ph.D.

Madhukar Trivedi, M.D.

Associate Editors

Olusola Ajilore, M.D., Ph.D.

Huda Akil, Ph.D.

Melissa Arbutckle, M.D., Ph.D.

Eraka P.J. Bath, M.D.

Karl Deisseroth, M.D., Ph.D.

Javier I. Escobar, M.D., M.Sc.

Julie L. Fudge, M.D.

Qiyong Gong, M.D., Ph.D.

Raquel E. Gur, M.D., Ph.D.

Helena Hansen, M.D., Ph.D.

David C. Henderson, M.D.

Yasmin Hurd, Ph.D.

Clinton D. Kilts, Ph.D.

Carlos López Jaramillo, M.D., M.Sc., Ph.D.

Joan L. Luby, M.D.

John C. Markowitz, M.D.

Helen S. Mayberg, M.D., F.R.C.P.C.

Terrie E. Moffitt, Ph.D.

Charles B. Nemeroff, M.D., Ph.D.

Roy Perlis, M.D.

Diego A. Pizzagalli, Ph.D.

Bryan L. Roth, M.D., Ph.D.

Alan F. Schatzberg, M.D.

Giulio Tononi, M.D., Ph.D.

Nim Tottenham, Ph.D.

John T. Walkup, M.D.

Editors Emeriti

Nancy C. Andreasen, M.D., Ph.D.

Robert Freedman, M.D.

Former Editors

Amariah Brigham, M.D., 1844–1849

T. Romeyn Beck, M.D., 1849–1854

John P. Gray, M.D., 1854–1886

G. Alder Blumer, M.D., 1886–1894

Richard Dewey, M.D., 1894–1897

Henry M. Hurd, M.D., 1897–1904

Edward N. Brush, M.D., 1904–1931

Clarence B. Farrar, M.D., 1931–1965

Francis J. Braceland, M.D., 1965–1978

John C. Nemiah, M.D., 1978–1993

Editorial Staff

Executive Editor

Michael D. Roy

Senior Editor

John J. Guardiano, Ph.D.

Production Manager

Susan Westrate

Staff Editor

Angela Moore

Online Content Manager

Aaron van Dorn

Editorial Support Services Manager

Heidi Koch-Bubel

Editorial Assistant

Linda LaCour

Editorial Assistant/ Permissions Coordinator

Megan Conley

Publisher

John McDuffie

PERSPECTIVES

EDITOR'S NOTE

1 Alcohol and Cannabis Use Disorders

Ned H. Kalin, M.D.

EDITORIALS

5 Intricacies of Researching Cannabis Use and Use Disorders Among Veterans in the United States

Catherine W. Striley, Ph.D., M.S.W., Carolin C. Hoeflich, M.S.

8 Cannabis and Psychosis: Recent Epidemiological Findings Continuing the "Causality Debate"

Suhas Ganesh, M.D., Deepak Cyril D'Souza, M.D.

11 Substance Use Disorders Are Deadly

Wilson M. Compton, M.D., M.P.E., Beth Han, M.D., Ph.D.

14 Identifying and Reducing Bias in Genome-Wide Association Studies of Alcohol-Related Traits

Henry R. Kranzler, M.D., et al.

17 2021 Articles of Import and Impact

The Editors

REVIEWS AND OVERVIEWS

21 Cannabis Use and the Endocannabinoid System: A Clinical Perspective

Margaret Haney, Ph.D.

Societal attitudes toward cannabis, both as a drug of abuse and as a potential therapeutic, have undergone a marked shift in the past 25 years, resulting in wide-scale changes in legalization, public policy, and marketing of cannabis and its constituents. The past few decades have also borne witness to a tremendous advancement in our understanding of the endocannabinoid system, beginning with the groundbreaking discoveries of the cannabinoid receptors and endogenous cannabinoids. With both the ubiquity of cannabis and cannabinoid use and the essential function of the endocannabinoid system, this review seeks to describe several key clinical issues regarding the interaction between cannabis use and endocannabinoid neurobiology.

NEW RESEARCH

ARTICLES

26 Prevalence and Correlates of Cannabis Use and Cannabis Use Disorder Among U.S. Veterans: Results From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III)

Kendall C. Browne, Ph.D., et al. EDITORIAL • CME

A clear risk for cannabis use disorder was evident among veterans reporting nonmedical cannabis use, with up to 37% meeting criteria for a cannabis use disorder in their lifetime. The odds of cannabis use and use disorder were higher among those of lower socioeconomic status and those with psychiatric and substance use disorders. Odds of use, daily or near daily use, and use disorder were even higher among veterans in states with medical marijuana laws.

Articles, continued

36 Association of Cannabis Use–Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001–2002 and 2012–2013

Ofir Livne, M.D., et al. EDITORIAL • CME

Data from two large-scale national U.S. epidemiological surveys conducted in 2001–2002 and 2012–2013 show that the prevalence of self-reported psychotic disorders in U.S. adults has significantly increased. Of four cannabis use predictors, two were associated with self-reported psychotic disorders in both time periods, and all four were associated in the more recent survey. This information can inform clinicians about the need for evaluation of cannabis use among those with psychosis to help determine appropriate interventions for individuals at risk.

46 The Impact of Alcohol and Other Substance Use Disorders on Mortality in Patients With Eating Disorders: A Nationwide Register-Based Retrospective Cohort Study

Angelina Isabella Mellentin, Ph.D., et al. EDITORIAL • CME

Presence of a substance use disorder (SUD) involving alcohol, cannabis, and hard drugs had an additive effect on all-cause mortality risk in a large sample of patients with eating disorders. These findings highlight the importance of focusing on SUD prevention and treatment in order to reduce excess mortality in eating disorder patients. This is particularly relevant for those with anorexia nervosa who abuse hard drugs because they were found to be the most susceptible to premature death. SUD appears to be the driving factor behind mortality in patients with bulimia nervosa; thus SUD prevention and treatment would help reduce mortality in bulimia.

58 Item-Level Genome-Wide Association Study of the Alcohol Use Disorders Identification Test in Three Population-Based Cohorts

Travis T. Mallard, M.A., et al. EDITORIAL

An examination of genetic data from more than 150,000 people concerning particular clinical aspects of alcohol use disorders found that some questionnaire items from a widely used alcohol use disorder screening tool possess stronger genetic information than other questionnaire items, moving genetic research one step closer to clinical utility for alcohol use disorders.

COMMUNICATIONS AND UPDATES

LETTERS TO THE EDITOR

71 Is a Diagnosis of Schizophrenia Spectrum Disorder Associated With Increased Mortality in Patients With COVID-19?

Marina Sánchez-Rico, M.P.H., et al.

73 Comment on “Elevated C-Reactive Protein in Patients With Depression, Independent of Genetic, Health, and Psychosocial Factors: Results From the UK Biobank”

Mark Kvarda, M.D., Ph.D., et al.

OTHER ITEMS OF INTEREST

4 Statistical Editors Sought

74 Highlights From the Residents’ Journal: December 2021

Cover: This issue is focused on providing a deeper understanding of the factors underlying alcohol and cannabis use and misuse in relation to the development of substance use disorders and interactions with other psychiatric illnesses. (Image by Spender1, shutterstock.com.)

THE AMERICAN PSYCHIATRIC ASSOCIATION

800 Maine Avenue, S.W., Suite 900, Washington, D.C. 20024
(888) 357-7924 (toll-free inside the U.S. and Canada)
web site: www.psychiatry.org • e-mail: apa@psych.org

Chairpersons of Councils, Committees, and Task Forces

Standing Committees

Bylaws	Edward R. Herman, J.D., M.D.
Elections	Justin W. Schoen, M.D.
Ethics	Charles Dike, M.D.
Finance and Budget	Ann T. Sullivan, M.D.
<i>Audit</i>	Ayana Jordan, M.D., Ph.D.
<i>Investment Oversight</i>	Steven S. Sharfstein, M.D.
Joint Reference	Rebecca W. Brendel, M.D., J.D.
Membership	Kimberly A. Gordon-Achebe, M.D.
Nominating	Jeffrey L. Geller, M.D., M.P.H.
Tellers	Mariam F. Aboukar, D.O.

Non-Standing Committee

Conflict of Interest	Sandra M. DeJong, M.D., M.Sc.
-----------------------------	-------------------------------

Councils

Council on Addiction Psychiatry

Smita Das, M.D., M.P.H., Ph.D.

Council on Advocacy and Government Relations

Katherine G. Kennedy, M.D.

Advocacy and Litigation Funding

Bhasker J. Dave, M.D.

Council on Children, Adolescents, and Their Families

Gabrielle Shapiro, M.D.

Women's Mental Health

Ludmila B. De Faria, M.D.

Council on Communications

Isabel K. Norian, M.D.

Council on Consultation-Liaison Psychiatry

Sejal B. Shah, M.D.

Council on Geriatric Psychiatry

Maria D. Llorente, M.D.

Council on Healthcare Systems and Financing

Robert L. Trestman, M.D., Ph.D.

Integrated Care

Benjamin G. Druss, M.D.

RBRVS, Codes and Reimbursement

Gregory G. Harris, M.D.

Reimbursement for Psychiatric Care

Laurence H. Miller, M.D.

Telepsychiatry

James H. Shore, M.D.

Council on International Psychiatry and Global Health

David C. Henderson, M.D.

Chester Pierce Human Rights Award Committee

Michelle P. Durham, M.D., M.P.H.

Council on Medical Education and Lifelong Learning

Eindra Khin Khin, M.D.

Innovation

Nina Vasan, M.D.

Scientific Program

Catherine C. Crone, M.D.

*Scientific Program—Mental Health Services Conference
(Oct. to Oct. tenure)*

Sarah Y. Vinson, M.D.

Vestermark Award Committee

Donna Marie Sudak, M.D.

Well-being and Burnout

Constance Guille, M.D.

Council on Minority Mental Health and Health Disparities

Walter Wilson, Jr., M.D.

Council on Psychiatry and Law

Debra A. Pinals, M.D.

Judicial Action

Reena Kapoor, M.D.

Council on Quality Care

Carol L. Alter, M.D.

Mental Health Information Technology

John Torous, M.D.

Quality and Performance Measurement

David S. Kroll, M.D.

Practice Guidelines

Daniel J. Anzia, M.D.

Council on Research

Jonathan E. Alpert, M.D., Ph.D.

Climate Change and Mental Health

Elizabeth Haase, M.D.

Psychiatric Dimensions of Disasters

Joshua C. Morganstein, M.D.

Go Online

Visit ajp.psychiatryonline.org for these features!

AJP in Advance *Discover the latest research advances before they appear in print*

Variable Patterns of Remission From ADHD in the Multimodal Treatment Study of ADHD

New findings challenge the evidence that 50% of children with ADHD recover by adulthood. Most youth with ADHD in the sample (90%) experienced brief periods of remission but only 10% demonstrated true recovery from ADHD by age 25. Most apparent remission was temporary, revealing ADHD as a fluctuating, rather than static, disorder.

Stanford Neuromodulation Therapy: A Double-Blind Randomized Controlled Trial

Results from a trial evaluating the efficacy of Stanford Neuromodulation Therapy (SNT) suggest the approach may be a reproducible, rapid, and highly effective treatment for severe, refractory depression. After five days of treatment, 79% of participants in the active SNT group achieved remission from their depressive episodes compared to 13% in the sham group. The short 5-day treatment course and high antidepressant efficacy of SNT present an opportunity to treat patients where rapid-acting treatments are needed, such as in the ER or inpatient settings.

AJP CME *Earn CME credit: 3 courses per issue*

You can earn CME credits by reading articles in *The American Journal of Psychiatry*. Three articles in this issue form a short course that consists of reading the article and answering three multiple-choice questions with a single correct answer for up to 1 *AMA PRA Category 1 Credit™* each. Credit is issued only to subscribers of the online AJP CME Course Program.

See the table below for the articles in this month's issue that are the subject of a CME quiz.

In this issue

Prevalence and Correlates of Cannabis Use and Cannabis Use Disorder Among U.S. Veterans: Results From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III) (p. 26)

Association of Cannabis Use–Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001–2002 and 2012–2013 (p. 36)

The Impact of Alcohol and Other Substance Use Disorders on Mortality in Patients With Eating Disorders: A Nationwide Register-Based Retrospective Cohort Study (p. 46)

History of Psychiatry *Revisit the field's rich history through the AJP Archive*

125 years ago this month: Static Electricity in the Treatment of Nervous and Mental Diseases

While presenting some encouraging results for this therapeutic modality, this report also contains an elegant description of a potential placebo effect: "Hope and confidence bridge over many a crisis, and faith in the physician and the value of his efforts is a therapeutic power that should never be carelessly shattered."

@APAPubJournals
Psychiatry Online



AMERICAN
PSYCHIATRIC
ASSOCIATION
PUBLISHING



www.appi.org
1-800-368-5777
appi@psych.org

CONNECTICUT DEPARTMENT OF MENTAL HEALTH AND ADDICTION SERVICES (DMHAS)

The State of Connecticut - the Constitution State or the Nutmeg State, is undeniably a stunning state. With the seasonal changes, landscapes ranging from coastlines to scenic mountain ranges, the state provides a variety of dynamic ambience and a bounty of natural charm and attraction year-round. Connecticut has lots of great schools, colleges and universities including Yale, University of Connecticut, and excellent community colleges.

Who we are: The Department of Mental Health and Addiction Services (DMHAS) has the responsibility to set forth policies to improve behavioral health care within the state. We are a large health care system comprised of eight facilities offering services across the continuum of care. All DMHAS facilities are accredited by The Joint Commission and has academic relationships with Yale University and the University of Connecticut medical schools.

Where we are located: Bridgeport, Danbury, Hartford, Middletown, New Haven, Norwich, Stamford, Torrington and Waterbury.

Who we service: Connecticut adults over 18 years of age with: psychiatric and/or substance use disorders, problem gambling disorders, substance abusing pregnant women, traumatic brain injury and special populations transitioning out of the Department of Children and Families.

What positions are available: Medical Directors, Psychiatrists & Forensic Psychiatrists full-time, part-time and per diem opportunities

What we offer: A comprehensive benefits and bonus package, job related license reimbursement; indemnification clause; Continuing Medical Education credit through onsite grand rounds and trainings; participation in Public Service Loan Forgiveness Program. Subject, to employment status and hours worked.

Contact us at DAS.SHRM@ct.gov OR visit

<https://www.jobapscloud.com/CT/> to view our available job openings.



Call for Nominations

The Institute of Living/Hartford Hospital is pleased to announce that nominations are now being accepted for the 2022 C. Charles Burlingame Award. This award, honoring an outstanding leader in psychiatric education, research or administration, is made in the memory of Dr. Burlingame, psychiatrist-in-chief from 1931 to 1950.

We invite you to nominate a person who has significantly advanced the field of psychiatry. The nomination must include a current curriculum vitae and two letters of support describing the candidate's achievements.

The Institute of Living is a comprehensive behavioral health system for the evaluation and treatment of psychiatric and addiction disorders. We offer a full continuum of services to patients and remain committed to the highest standards of clinical care, research and education.

Past Recipients

1988 Robert Kellner, M.D., Ph.D.	2005 Herbert D. Kleber, M.D.
1989 William T. Carpenter, Jr., M.D.	2006 Daniel N. Stern, M.D.
1990 Dennis P. Cantwell, M.D.	2007 Jerrold F. Rosenbaum, M.D.
1991 George E. Vaillant, M.D.	2008 K. Ranga Rama Krishnan, M.D.
1992 A. John Rush, M.D.	2009 David J. Kupfer, M.D.
1993 John C. Nemiah, M.D.	2010 Professor Sir Michael Rutter
1994 Maurice J. Martin, M.D.	2011 Jeffrey A. Lieberman, M.D.
1995 Otto F. Kernberg, M.D.	2012 Judith L. Rapoport, M.D.
1996 Charles P. O'Brien, M.D., Ph.D.	2013 Nora D. Volkow, M.D.
1997 Glen Owen Gabbard, M.D.	2014 Daniel R. Weinberger, M.D.
1998 Lissy F. Jarvik, M.D., Ph.D.	2015 David A. Brent, M.D.
1999 Nancy C. Andreasen, M.D., Ph.D.	2016 Steven S. Sharfstein, M.D.
2000 Lewis L. Judd, M.D.	2017 Harold Alan Pincus, M.D.
2001 Paul S. Appelbaum, M.D.	2018 Kenneth S. Kendler, M.D.
2002 Charles B. Nemeroff, M.D., Ph.D.	2019 Max Fink, M.D.
2003 Dilip V. Jeste, M.D.	2020 Ned H. Kalin, M.D.
2004 David H. Barlow, Ph.D.	2021 Herbert Y. Meltzer, M.D.

**Hartford
HealthCare**
Institute of Living

Nominations should be sent no later than March 18, 2022 to:
Javed Sukhera, MD, PhD
Chair/Chief of Psychiatry
Institute of Living/Hartford Hospital
200 Retreat Ave., Hartford, CT 06106
or e-mail to Faye.Jenkins@hhchealth.org



If you're dedicated to elevating mental health care...

YOU BELONG HERE.

**No disability evaluations. No benzodiazepines.
No stimulants. No insurance companies.**

- 40-hour workweek with flexible schedules, including 4/10s
- Thank You Bonus up to \$20k for professionals newly hired with the State of CA
- Generous paid time off and holiday schedule
- Multiple locations throughout CA
- 401(k) and 457 plans (tax defer up to \$39k – \$52k per year)
- Paid malpractice insurance, license, and DEA renewal
- Relocation assistance for professionals newly hired with the State of CA
- Visa sponsorship opportunities
- State of CA retirement that vests in five years (visit www.CalPERS.ca.gov for retirement formulas)

**PSYCHIATRISTS | INPATIENT
OUTPATIENT**

\$280,344 – \$336,864
annual salary (Board Certified)

\$273,156 – \$327,360
annual salary (Board Eligible)



Submit your CV to CentralizedHiringUnit@cdcr.ca.gov or apply online at www.cchcs.ca.gov.

Salary depending on experience.

